Plains Venture PartnersPlains Venture PartnersPlains Venture PartnersPlains Venture Partners
  • About
  • Portfolio
  • Team
  • Investor Login

Simergent Closes $2.835M Seed Round

    Home News Simergent Closes $2.835M Seed Round
    NextPrevious

    Simergent Closes $2.835M Seed Round

    By sarah | News | 0 comment | 24 April, 2019 | 0

    OKLAHOMA CITY, OK and CHICAGO, IL April 18, 2019 – Simergent closed a $2.835M seed round to continue developing an affordable home dialysis system for the US and abroad. Simergent’s Archimedes automated peritoneal dialysis system will allow access to home dialysis at a much more affordable price point with world-class patient usability and patient safety features.

    Medicare currently spends over $35 billion per year on dialysis patients, representing over 7% of the entire Medicare budget. Globally, home dialysis is currently inaccessible or unaffordable by many end stage renal disease patients, with 2.3 million patients dying each year as a result. Simergent’s device aims to reduce healthcare expenditures, improve patient health, and make it easier for patients to perform dialysis at home.

    i2E, Inc., led the round with investment of $1.475 million that included $750,000 from the Oklahoma Seed Capital Fund, $500,000 from the Oklahoma Angel Fund and $225,000 from the i2E-managed SeedStep Angels.

    Funding will be used to complete design, manufacturing, and regulatory testing activities required for FDA clearance.

    “Anyone who wants to perform dialysis at home should have the opportunity to do so. Simergent’s Archimedes system should help stem the tide of rapidly increasing Medicare and private insurance dialysis expenditures. With recent market trends moving toward home dialysis, we feel Simergent is uniquely positioned to disrupt the global dialysis market,” said Steve Lindo, Simergent’s co-founder and CEO. “We’re humbled at the tremendous response we’ve received from i2E and all of our investors to increase access to home dialysis.”

    About Simergent

    Simergent is committed to patient-centered home dialysis innovation aimed at reducing cost and improving patients’ quality of life. Simergent’s Archimedes system is not yet FDA-cleared for use. Simergent has offices in Oklahoma City, OK and Chicago, IL as part of the renowned MATTER healthtech incubator. For more information visit https://www.simergent.com/.

    For more information, contact Simergent at sjlindo@simergent.com.

    Oklahoma Angel Fund, Oklahoma Seed Capital Fund, SeedStep Angels, Simergent, Steve Lindo

    Related Post

    • Norman’s IMMY has global impact, despite humble beginnings

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019 The Oklahoman Sean and Scott Bauman, CEO and chief operating officer of biotechnology company IMMY, literally grew up in the family business. “There isn’t a job that my brotherRead more

    • Oklahoma’s bioscience prowess busy making a difference worldwide

      By sarah | 0 comment

      By Kevan Goff-ParkerCopyright © 2019 The Oklahoman Greater Oklahoma City Chamber Manager of Innovation and Entrepreneurship Evan Fay said he believes some people may be caught off-guard by Oklahoma’s growing bioscience prowess. He made hisRead more

    • Ascend BioVentures helps determine right path for health care discoveries

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019, The Oklahoman It’s really difficult to invent new drug therapies. Research and development can take decades. Once a potential drug appears viable, testing for safety and efficacy adds moreRead more

    • OSU delegates share future bioscience innovations with leaders

      By sarah | 0 comment

      By Kevan Goff-Parker Copyright © 2019, The Oklahoman PHILADELPHIA — Three Oklahoma State University researchers this week have been connecting face-to-face with some of the world’s top bioscience companies during the 2019 BIO International ConventionRead more

    • Delegation Sharing Oklahoma’s Good News Bioscience Story at BIO International Convention

      By sarah | 0 comment

      By Kevan Goff-Parker Copyright ©2019, The Oklahoman PHILADELPHIA — More than 40 Oklahoma bioscience and industry experts from a wide array of fields are busy telling global industry leaders about the state’s successes in theRead more

    Leave a Comment

    Cancel reply

    You must be logged in to post a comment.

    NextPrevious

    Investor Login

    • Disclaimer & Disclosure

    Oklahoma City Location

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305

    Click HERE for directions.

    Tulsa Location

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592

    Click HERE for directions.

    • Disclaimer & Disclosure
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • About
    • Portfolio
    • Team
    • Funds
    • Investor Login
    Plains Venture Partners